EKSO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EKSO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Ekso Bionics Holdings's Sloan Ratio for the quarter that ended in Mar. 2024 was -9.70%.
As of Mar. 2024, Ekso Bionics Holdings has a Sloan Ratio of -9.70%, indicating the company is in the safe zone and there is no funny business with accruals.
The historical data trend for Ekso Bionics Holdings's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ekso Bionics Holdings Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Sloan Ratio % | Get a 7-Day Free Trial | 16.88 | - | 2.95 | 11.69 | -10.33 |
Ekso Bionics Holdings Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Sloan Ratio % | Get a 7-Day Free Trial | - | - | - | -10.33 | -9.70 |
For the Medical Instruments & Supplies subindustry, Ekso Bionics Holdings's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Ekso Bionics Holdings's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Ekso Bionics Holdings's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Ekso Bionics Holdings's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Sloan Ratio | = | (Net Income (A: Dec. 2023 ) | - | Cash Flow from Operations (A: Dec. 2023 ) |
- | Cash Flow from Investing (A: Dec. 2023 )) | / | Total Assets (A: Dec. 2023 ) | |
= | (-15.198 | - | -12.054 | |
- | -0.157) | / | 28.918 | |
= | -10.33% |
Ekso Bionics Holdings's Sloan Ratio for the quarter that ended in Mar. 2024 is calculated as
Sloan Ratio | = | (Net Income (TTM) | - | Cash Flow from Operations (TTM)) |
- | Cash Flow from Investing (TTM)) | / | Total Assets (Q: Mar. 2024 ) | |
= | (-14.238 | - | -11.306 | |
- | -0.123) | / | 28.957 | |
= | -9.70% |
Ekso Bionics Holdings's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was -4.23 (Jun. 2023 ) + -3.365 (Sep. 2023 ) + -3.214 (Dec. 2023 ) + -3.429 (Mar. 2024 ) = $-14.24 Mil. Ekso Bionics Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was -2.903 (Jun. 2023 ) + -3.353 (Sep. 2023 ) + -1.584 (Dec. 2023 ) + -3.466 (Mar. 2024 ) = $-11.31 Mil. Ekso Bionics Holdings's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was -0.055 (Jun. 2023 ) + -0.017 (Sep. 2023 ) + -0.043 (Dec. 2023 ) + -0.008 (Mar. 2024 ) = $-0.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ekso Bionics Holdings (NAS:EKSO) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
According to How to Beat the Market with the Sloan Ratio:
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2024, Ekso Bionics Holdings has a Sloan Ratio of -9.70%, indicating the company is in the safe zone and there is no funny business with accruals.
Thank you for viewing the detailed overview of Ekso Bionics Holdings's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Jerome Wong | officer: Interim CFO | C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804 |
Scott G. Davis | officer: President & COO | C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804 |
Steven Sherman | director | |
Jason C Jones | officer: VP of Product Development | EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804 |
John Glenn | officer: Chief Financial Officer | 7900 HOPYARD ROAD, APT 210, PLEASANTON CA 94577 |
Lathan Corinna | director | 140 KENDRICK STREET, NEEDHAM MA 02494 |
William R Shaw | officer: See Remarks | 1414 HARBOUR WAY SOUTH, SUITE 1201, C/O EKSO BIONICS HOLDINGS, INC., RICHMOND CA 94804 |
Rhonda A. Wallen | director | C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804 |
Mary Ann Cloyd | director | 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059 |
Combest Development (hong Kong) Ltd | 10 percent owner | ROOM 2210, CC WU BUILDING 302, HENNESSY ROAD, WAN CHAI, HONG KONG K3 999077 |
Jack Peurach | director, officer: Chief Executive Officer | 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804 |
Thomas A Schreck | director | 10240 BUBB RD, CUPERTINO CA 95014 |
Puissance Capital Management Lp | 10 percent owner | 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Christian Babini | officer: VP of Sales, Americas | C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1, RICHMOND CA 94804 |
Puissance Cross-border Opportunities Ii Llc | 10 percent owner | C/O PUISSANCE CAPITAL FUND (GP) LLC, 950 THIRD AVENUE, NEW YORK NY 10022 |
From GuruFocus
By sperokesalga sperokesalga • 04-27-2023
By Value_Insider Value_Insider • 12-05-2022
By Marketwired • 07-27-2023
By GuruFocusNews GuruFocusNews • 07-06-2022
By sperokesalga sperokesalga • 04-20-2023
By PRNewswire PRNewswire • 07-03-2022
By sperokesalga sperokesalga • 03-20-2023
By Value_Insider Value_Insider • 10-27-2022
By PRNewswire PRNewswire • 06-23-2022
By PurpleRose PurpleRose • 07-13-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.